Teva Pharmaceutical Industries (TEVJF) EBIT Margin (2016 - 2026)

Teva Pharmaceutical Industries has disclosed EBIT Margin across 11 years of filings, most recently posting 16.37% for Q1 2026.

• Quarterly EBIT Margin rose 304.0% year-over-year to 16.37% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 13.19% (up 1035.0% YoY) and the FY2025 annual result came in at 12.5%, up 1433.0% from the prior year.
• EBIT Margin rose to 16.37% in Q1 2026, from 6.37% in the prior quarter.
• Over five years, EBIT Margin peaked at 19.69% in Q3 2025 and troughed at 25.54% in Q2 2022.
• A 5-year average of 0.58% and a median of 0.12% in 2024 frame the typical range for EBIT Margin.
• Annual changes were most pronounced in 2022 — EBIT Margin tumbled 4043 bps — and 2023, when it soared 4116 bps.
• Tracing TEVJF's EBIT Margin over 5 years: stood at 24.2% in 2022, then surged by 170 bps to 16.96% in 2023, then tumbled by 106 bps to 1.0% in 2024, then surged by 737 bps to 6.37% in 2025, then surged by 157 bps to 16.37% in 2026.
• Business Quant data shows TEVJF's EBIT Margin at 16.37% in Q1 2026, 6.37% in Q4 2025, and 19.69% in Q3 2025.